Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

p27 Activates CDK4 and Blocks Palbociclib-Mediated CDK4 Inhibition

DOI: 10.1158/2159-8290.CD-RW2020-001 Published February 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Structural and biochemical studies revealed how p27 interacts with and activates CDK4.

  • Concept: p27 binding prevented inhibition of CDK4 by palbociclib, a CDK4/6 inhibitor used in the clinic.

  • Impact: Palbociclib may not work as previously envisioned, and p27′s role in CDK4 regulation is complex.


Embedded Image

Some CDK4/6 inhibitors are approved for the treatment of HER2-negative, ER-positive breast cancer and are being investigated for the treatment of other cancers in clinical trials; however, questions remain about CDK4 regulation. Guiley and colleagues investigated CDK4 regulation by the intrinsically disordered proteins p21 and p27, which have seemingly contradictory roles in CDK4 regulation: Some evidence shows that they are CDK inhibitors, but other evidence indicates that they are required for CDK4–cyclin D assembly and activity in vivo. Crystal structures of the p21–CDK4–cyclin D1 and p27–CDK4–cyclin D1 trimer complexes revealed that p21′s and p27′s inhibitory functions may arise from their blockage of a substrate-docking site on cyclin D and the fact that interactions with either one's D2 domains shifts some amino-acid residues that form part of CDK4′s ATP-binding pocket. Interestingly, though, comparison of these trimer structures with the structure of the previously published CDK4–cyclin D dimer complex revealed that binding of p21 or p27 caused rotation of the N-lobe of CDK4 relative to the C-lobe, releasing the activation segment of the protein from the active site, and caused a rearrangement that poised the catalytic lysine residue for activity. Thus, while still inhibited, the trimer conformations may represent intermediates along the pathway to activation. Biochemical studies showed that tyrosine phosphorylation of p27, but not p21, led to increased RB phosphorylation by CDK4, and a structure of the phospho-p27–CDK4–cyclin D complex indicated that this effect was due to relief from inhibition by p27′s D2 domain, which binds CDK4′s N-lobe. Notably, the CDK4/6 inhibitor palbociclib could not bind p27–CDK4–cyclin D trimers and poorly inhibited these trimers both in vitro and in a breast cancer cell line. Instead, palbociclib primarily bound CDK4/6 monomers in cells, and treatment appeared to indirectly cause CDK2 inhibition, indicating that its mechanism may be different than what is generally thought. In summary, this study provides mechanistic insight into a process important in cancer and sheds light on a potentially misunderstood drug mechanism.

Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 2019;366. pii: eaaw2106.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
p27 Activates CDK4 and Blocks Palbociclib-Mediated CDK4 Inhibition
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
p27 Activates CDK4 and Blocks Palbociclib-Mediated CDK4 Inhibition
Cancer Discov February 1 2020 (10) (2) 172; DOI: 10.1158/2159-8290.CD-RW2020-001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
p27 Activates CDK4 and Blocks Palbociclib-Mediated CDK4 Inhibition
Cancer Discov February 1 2020 (10) (2) 172; DOI: 10.1158/2159-8290.CD-RW2020-001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Structural Biology

  • Checkpoint Kinase MEC1 (ATR) Structure Reveals Activation Mechanism
  • Trametinib Promotes MEK Binding to the RAF-Family Pseudokinase KSR
  • Therapeutic CD20-Targeting Antibodies Differ in Their Binding Modes
Show more Structural Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement